Lumida
/NUTX
⌘K
Nutex Health Inc

Nutex Health Inc

NUTX
$162.98USD↓-0.86%-1.42 today

MARKET CAP

1.1B

P/E (TTM)

12.5x

FWD P/E

7.7x

DAY RANGE

$158 – $168

52W RANGE

$77
$204

AI Summary

Stalk
StalkMedium

In Stage 2 advancing environment, NUTX maintains a medium-term bullish bias despite recent support failure at the $173 zone and early momentum loss. Price remains above the rising 50 DMA, anchoring upside potential, while 9/21 EMAs cap rallies, indicating caution. Short-term timing is unfavorable for entries as price trades below falling EMAs with distribution pressure evident. We recommend stalking for a disciplined re-entry into the uptrend near structural support, awaiting a clean pullback into the rising 50 DMA or reclaim of the 9/21 EMA zone to confirm resumption.

  • ↑Q1 2025 revenue grew 214% YoY to $211.8M; adjusted EBITDA $72.8M
  • ↑Arbitration drives 71% of hospital revenue with >85% win rate for cash predictability
  • ↓Dependence on arbitration under IDR exposes revenue to potential regulatory reversals; $55M cut last cycle
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Nutex Health, Inc. (NASDAQ: NUTX) is a leading provider of micro-hospitals, specializing in delivering patient-centered care across a rapidly expanding network of facilities throughout the U.S. The company operates on a unique model that emphasizes value-based care and operational efficiency, leveraging regulatory frameworks such as the No Surprises Act to enhance reimbursement processes. With a focus on community engagement and high-quality services, Nutex aims to transform healthcare delivery while maintaining a strong emphasis on profitability and shareholder value.

Bull says

  • ↑Q1 2025 revenue grew 214% YoY to $211.8M; adjusted EBITDA $72.8M
  • ↑Arbitration drives 71% of hospital revenue with >85% win rate for cash predictability
  • ↑Three new hospitals planned in 2026 to capture market demand and diversify revenue
  • ↑Strong liquidity with $87.7M cash and $25M share repurchase bolstering capital returns
  • ↑Patient satisfaction tops 96%, indicating high demand and retention
  • ↑High growth potential, robust balance sheet strength, favorable momentum, and institutional interest

Bear says

  • ↓Dependence on arbitration under IDR exposes revenue to potential regulatory reversals; $55M cut last cycle
  • ↓Operating expenses at ~49.2% of revenue; arbitration and staffing costs pressure margins
  • ↓Patient visits rose just 3.1% in Q1 2026, raising volume growth concerns
  • ↓New hospitals cost $20–30M each, increasing reliance on external financing and debt
  • ↓Low earnings yield and profitability metrics suggest challenges in generating sustainable returns
  • ↓High leverage and interest-rate sensitivity heighten financial risk; negative dividend yield signals cash constraints

Investment themes with NUTX

Health Care Providers↑ +0.29%

HCA · DGX · UHS
Most Shorted Stocks↑ +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-02-2026neutral

Transcript signals

Bull points

  • Operationally, overall hospital visits increased year over year, reflected continued demand across our markets, and steady contributions from both newer and more established facilities.
  • These actions are improving patient retention, supporting stronger clinical outcomes, and reinforcing the operating leverage built into our model.
  • As facilities continue to develop and utilization patterns normalize, we expect these efforts to continue supporting operating leverage and margin stability.

Bear points

  • operating expenses increased during the quarter, driven primarily by higher patient volumes, increasing vacuity, and intentional staffing investments.
  • Gross profit for the three months ended March 31, 2026, was $91.7 million, or 42.4% of total revenue, as compared to $118.3 million or 55.9% of total revenue in the same period in 2025, a 13.5% decrease for the three months ended March of 2026 versus 2025.
  • Adjusted EBITDA attributable to NewTex decreased by $15.3 million, or 21%, from $72.8 million in Q1 of 2025 to $57.6 million in Q1 of 2026.
Read full transcript analysis ›